Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II controlled study of PM01183 in platinum-resistant/refractory advanced ovarian cancer
2011-002172-16Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Aug 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lurbinectedin in ovarian cancer (3 arms), sponsored by PharmaMar. Primary endpoint: Primary antitumor activity. Started Aug 2011; status: completed.
02
Drugs
lurbinectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2011-002172-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002172-16.